Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
Hepatocellular carcinoma (HCC) or liver cancer is the most common primary malignant tumor of the liver, which is characterized on the first place by a poor prognosis. HCC was diagnosed in 92 patients (62.6%) in 2019 and the period from January to April 2020 in the Republic of Bashkortostan, and amon...
Guardado en:
Autores principales: | Konstantin V. Menshikov, Aleksandr V. Sultanbaev, Kamila T. Akhmetgareeva, Danila O. Lipatov |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c0cfd0526a68496b9746ee7f2af922a5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
por: L. V. Bolotina
Publicado: (2020) -
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Xiaozhun Huang, et al.
Publicado: (2021) -
The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Jie Zhu, et al.
Publicado: (2021) -
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tetsu Tomonari, et al.
Publicado: (2021) -
Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo
por: Ching-Hsuan Wu, et al.
Publicado: (2022)